GEN Exclusives

More »

GEN News Highlights

More »
Oct 18, 2006

Orchid Cellmark’s Contract Extension Potentially Worth $3.5M annually

  • Orchid Cellmark’s scrapie genotyping contract has been extedend by the U.K. government through to 2008. The extension is expected to be worth in excess of $3.5 million annually.

    Under the terms of the agreement, Orchid Cellmark will become the exclusive supplier of genotyping services offered to sheep farmers under the government's National Scrapie Plan for Great Britain, which is designed to help British farmers breed sheep with reduced genetic susceptibility to the prion disease scrapie.

    "Orchid Cellmark has been the major supplier of high-throughput genotyping services to the British National Scrapie Plan since its inception,” points out Thomas Bologna, president and CEO. “We believe that this extension of our scrapie genotyping contract, now on an exclusive basis, is an indication of the overall strength of our U.K. operations."

    Orchid Cellmark’s genotyping service has analyzed the DNA of approximately two million sheep under this program since 2001.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »